⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1481779 | 1.00 | — | — | |
| SCHEMBL941274 | 1.00 | — | — | |
| Water SCHEMBL17784188 | 0.98 | — | — | |
| Water SCHEMBL18335173 | 0.98 | — | — | |
| SCHEMBL3261178 | 0.82 | — | — | |
| SCHEMBL8763574 | 0.78 | — | — | |
| SCHEMBL10433530 | 0.73 | — | — | |
| SCHEMBL7212258 | 0.69 | ALDH1A1 (0.30) | — | |
| SCHEMBL7636677 | 0.67 | KDM4E (0.31) | — | |
| SCHEMBL7642834 | 0.67 | KDM4E (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10842784-B2 | Treatment of energy utilization disease | VIDA PHARMA LIMITED (GB) | 2020-11-24 | — | — | US | disclosed |
| EP-2257286-B1 | TREATMENT OF ENERGY UTILIZATION DISEASE | SUMMIT CORP PLC (GB) | 2016-12-28 | — | — | EP | disclosed |
| US-20160151341-A1 | TREATMENT OF ENERGY UTILIZATION DISEASE | SUMMIT CORPORATION PLC (GB) | 2016-06-02 | — | — | US | disclosed |
| US-20110015226-A1 | Treatment of Energy Utilization Disease | SUMMIT CORPORATION PLC (GB) | 2011-01-20 | — | — | US | disclosed |
| EP-2257286-A1 | TREATMENT OF ENERGY UTILIZATION DISEASE | Summit Corporation Plc (GB) | 2010-12-08 | — | — | EP | disclosed |
| WO-2009103953-A1 | TREATMENT OF ENERGY UTILIZATION DISEASE | SUMMIT CORPORATION PLC (GB) | 2009-08-27 | — | — | WO | disclosed |
| EP-0439444-A2 | Synthesis of chiral pyrrolidine and piperidine glycosidase inhibitors | MONSANTO COMPANY (US) | 1991-07-31 | — | — | EP | disclosed |
| US-5013842-A | Synthesis of chiral pyrrolidine and piperidine glycosidase inhibitors | MONSANTO COMPANY (US) | 1991-05-07 | — | — | US | disclosed |